RBC Downgrades Regeneron Pharmaceuticals (REGN) to Sector Perform
More News related to REGN
- Merriman Curhan Ford Reiterates a 'Buy' on Regeneron (REGN); Raising Target Range
- Morning Movers 11/11: NCST, SMI, MSN, CHLN, NLST, REGN Higher; TGIC, STS, CLWR, STV, MHR, MBLX Lower
- Sanofi-aventis (SNY) and Regeneron Pharmaceuticals (REGN) to Expand Global Collaboration
- Regeneron Announces Conference Call to Discuss Expanded Antibody Collaboration with Sanofi-aventis
- Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
RBC downgrades Regeneron Pharmaceuticals (Nasdaq: REGN) from Outperform to Sector Perform.
To see more analyst ratings on REGN Click Here.
Regeneron Pharmaceuticals, Inc., an integrated biopharmaceutical company, discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions in the United States.
Related Categories
DowngradesStocks Mentioned
-0.21Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
